SEARCH

SEARCH BY CITATION

References

  • 1
    Cvitkovic, E., Hayes, D. M., and Golbey, R.: Primary combination chemotherapy (VAB III) for metastatic or unresectable germ cell tumors. Proc. Am. Soc. Clin. Oncol. 17: 296 1976.
  • 2
    Cvitkovic, E., Spaulding, J. T., Bethune, Martin, J., and Whitmore, W. F.Jr,: Improvement of cis-dichlorodiam-mine platinum (NSC 119875) therapeutic index in an animal model. Cancer 39: 13571361.
  • 3
    DeConti, R. C., Toftness, B. R., Lange, R. C., and Crecasey, W. A.: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33: 13101315, 1973.
  • 4
    Dixon, R. L., Cooney, D. A., Davis, R. D. et al.: Preclinical toxicological evaluation of cis-dichlorodiammineplatinum (II). Proceedings of the 7th International Congress of Chemotherapy, Prague, 1971, Vol. II, pp. 243245.
  • 5
    Ellerby, R. A., Davis, H. L., Ansfield, F. J., and Ramirez, G.: Phase I clinical trial of combined therapy with 5 FU (NSC 19893) and cis-platinum (II) diamminedichloride (NSC 119875). Cancer 34: 10051010, 1974.
  • 6
    Forni, A. M., Koss, L. C., and Geller, W.: Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder in man. Cancer 17: 13481355, 1964.
  • 7
    Gonzalez-Vitale, J. C., Hayes, D. M., Cvitkovic, E. and Sternberg, S. S.: Renal toxicity associated with concomitant cis-platinum (II) diamminedichloride and gentamicincephalotin therapies (in preparation).
  • 8
    Hardaker, W. T., Stone, R. A., and McCoy, R.: Platinum nephrotoxicity. Cancer 34: 10301032, 1974.
  • 9
    Hayes, D. M., Cvitkovic, E., Golbey, R., Scheiner, E. and Krakoff, I. H.: Amelioration of renal toxicity of high dose cis-platinum diamminedichloride (CPDD) by manni-tol-induced diuresis. Proc. Am. Assoc. Cancer Res. 17: 169 1976.
  • 10
    Hill, J. M., Loeb, E., Speer, R. J., MacLellan, A. and Hill, N. O.: Cis-platinous diammino dichloride (P.D.D.) therapy of various malignant diseases. Proc. Am. Assoc. Cancer Res. 13: 20, 1972.
  • 11
    Hill, J. M., Speer, R. J., Loeb, E. et al.: Clinical experience with cis-platinous diammine dichloride (P.D.D.) Proceedings of the 7th International Congress of Chemotherapy, Prague, 1971. Vol II. pp 255257.
  • 12
    Horacek, P., and Drobnik, J.: Interaction of cis-Dichloro-diammineplatinum (II) with DNA. Biochem. Biophys. Acta 254: 341347, 1971.
  • 13
    Kociba, R. J., Sleight, S. D., and Rosenberg, B.: Inhibition of Dunning ascitic leukemia and Walker 256 carcino-sarcoma with cis-diamminedichloroplatinum (NSC 119875). Cancer Chemother. Rep. 54: 325329, 1970.
  • 14
    Kociba, R. J., and Sleight, S. D.: Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep. 55: 18, 1971.
  • 15
    Leonard, B. J., Eccleston, E., Jones, D., Todd, P. and Walpole, A.: Antileukaemic and nephrotoxic properties of platinum compounds. Nature 234: 4345, 1971.
  • 16
    Lippman, A. J., Helson, C., Helson, L. and Krakoff, I. H.: Clinical trials of cis-diamminedichloroplatinum (NSC119875). Cancer Chemother. Rep 57: 191200, 1973.
  • 17
    Piel, I. J., and Perlia, C. P.: Phase II Study of cis-dichlorodiammineplatinum (II) (NSC-119875) in combination with cyclophosphamide (NSC 26271) in the treatment of human malignancies. Cancer Chemother. Rep 59: 995999, 1975.
  • 18
    Rosenberg, B., Van Camp, L., Trosko, J. M., and Mansour, V. H.: Platinum compounds: A new class of potent antitumor agents. Nature 222: 385386, 1969.
  • 19
    Rosenberg, B., and Van Camp, L.: The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 30: 17991802, 1970.
  • 20
    Schaeppi, U., Heyman, I. A., Fleischman, R. W. Cis-dichlorodiammineplatinum (II) (NSC 119875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicol. Appl. Pharmacol. 25: 230241, 1973.
  • 21
    Sirica, A., Venditti, J. M., and Kline, L.: Enhanced survival response of L1210 leukemic mice to a single combination treatment with cis-platinum (II) diamminedichloride (cis-Pt-II; NSC 26271). Proc. Am. Assoc. Cancer Res. 12: 4, 1971.
  • 22
    Slavin, R. E., Millan, J. C., and Mullins, G. M.: Pathology of high dose intermittent cyclophosphamide therapy. Hum. Pathol. 6: 693709, 1975.
  • 23
    Yagoda, A., Watson, R. C., Gonzalez-Vitale, J. C., Grabstald, H., and Whitmore, W. F.Jr,.: Cis-dichlorodiammine platinum II in advanced urinary tract cancer. Cancer Chemother. Res. (in press.).